Levetiracetam
Product Images NDC 50090-2456

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-2456). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 01

The given text describes a formula to calculate the total daily dose in mL per day, based on the patient's weight and the daily dose in milligrams per kilogram (mg/kg/day). The formula involves multiplying the patient's weight (in kilograms) with the daily dose and dividing by the concentration of the medication (100 mg/mL).*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 02

This appears to be a formula for estimating renal clearance (CLer) in adult patients. It involves multiplying 140 minus the patient's age in years by their weight in kilograms, divided by 72 times their serum creatinine levels in milligrams per deciliter (mg/dL), with an adjustment factor of 0.85 for female patients. The calculation is then adjusted for body surface area (BSA) by dividing by the subject's BSA in square meters (m²) multiplied by 1.73. However, this formula should only be used as a guide and actual renal clearance may vary depending on other factors.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 03

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 04

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 05

This appears to be a table displaying the percentages of patients in a study who received different doses of a drug called Levetiracetam and a placebo. The doses of Levetiracetam were 1000mg/day and 2000mg/day. The table does not provide any additional context or information about the study or what Levetiracetam is used for.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 06

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 07

This table represents the percentage of patients who received either placebo or levetiracetam and experienced specific outcomes. The outcomes represented are not mentioned and there appears to be some missing data denoted by "%" and "o."*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 08

This text provides information on the percentage of patients who took either a Placebo or Levetiracetam and the corresponding number of patients in each group. Specifically, 19.6% (n=51) of patients took the Placebo while 43.1% (n=58) took Levetiracetam.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 09

The given text represents a table showing the percentage of patients under Placebo and Levetiracetam. The table consists of 10 rows where the first row gives the percentage from 100% to 0% and the fourth row is displaying two drug types namely Placebo with 84 patients and Levetiracetam with 79 patients. The remaining rows show the percentage of patients that reacted to the respective drugs, where 45.2% reacted to Placebo while 72.2% reacted to Levetiracetam.*

FDA Label Image

Label Image (Lbl500902456)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.